Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 3/20 | 0.45 |
| ▸ | CNR2 | P34972 | 3/20 | 0.45 |
| ▸ | RBP4 | P02753 | 5/20 | 0.44 |
| ▸ | APLNR | P35414 | 1/20 | 0.43 |
| ▸ | TTR | P02766 | 1/20 | 0.42 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.39 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2027673 | 0.86 | RBP4 (0.47) | ALDH1A1L3MBTL1CNR1CNR2RBP4 | |
| SCHEMBL2034427 | 0.78 | ALDH1A1 (0.45) | ALDH1A1L3MBTL1RBP4APLNRHCAR1 | |
| SCHEMBL2031113 | 0.78 | NR3C2 (0.47) | ALDH1A1CNR1CNR2HTR2AHTR2C | |
| SCHEMBL2031644 | 0.73 | ALDH1A1 (0.45) | ALDH1A1L3MBTL1RBP4APLNRHCAR1 | |
| SCHEMBL2025066 | 0.72 | POLB (0.49) | ALDH1A1L3MBTL1CNR1CNR2RBP4 | |
| SCHEMBL4727274 | 0.70 | ALDH1A1 (0.45) | ALDH1A1L3MBTL1RBP4APLNRTTR | |
| SCHEMBL1380808 | 0.70 | NOTUM (0.69) | ALDH1A1 | |
| SCHEMBL4729990 | 0.69 | ALDH1A1 (0.44) | ALDH1A1L3MBTL1CNR1CNR2RBP4 | |
| Hydrochloric Acid SCHEMBL2025123 | 0.69 | NOTUM (0.68) | ALDH1A1 | |
| SCHEMBL4559786 | 0.68 | L3MBTL1 (0.46) | ALDH1A1L3MBTL1APLNRHCAR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1844020-A1 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTOR LIGANDS | Exelixis, Inc. (US) | 2007-10-17 | — | — | EP | claimed |
| WO-2007024744-A2 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTOR LIGANDS | EXELIXIS, INC. (US) | 2007-03-01 | — | — | WO | claimed |
| WO-2006076202-A1 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTORS LIGANDS | EXELIXIS, INC. (US) | 2006-07-20 | — | — | WO | claimed |
| EP-1844020-B1 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTOR LIGANDS | EXELIXIS INC (US) | 2017-09-06 | — | — | EP | disclosed |
| EP-1844020-B1 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTOR LIGANDS | EXELIXIS INC (US) | 2017-09-06 | — | — | EP | disclosed |
| US-20110144128-A1 | Heterocyclic Carboxamide Compounds as Steroid Nuclear Receptors Ligands | EXELIXIS, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110144128-A1 | Heterocyclic Carboxamide Compounds as Steroid Nuclear Receptors Ligands | EXELIXIS, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| EP-1844020-A1 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTOR LIGANDS | Exelixis, Inc. (US) | 2007-10-17 | — | — | EP | disclosed |
| WO-2007024744-A2 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTOR LIGANDS | EXELIXIS, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| WO-2007024744-A2 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTOR LIGANDS | EXELIXIS, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| WO-2006076202-A1 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTORS LIGANDS | EXELIXIS, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144128-A1 | Heterocyclic Carboxamide Compounds as Steroid Nuclear Receptors Ligands | NCOA1, NCOA2, NCOA3 | ALDH1A1 1665/4885L3MBTL1 4870/4885CNR1 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.